Opinion of the Transparency Council – propafenonum
At its meeting on 14 October 2024, the Transparency Council adopted opinion No. 164/2024 on the covering the reimbursement of medicines containing the active substance propafenonum in terms of indications for use or dosage or route of administration different from those specified in the Summary of Product Characteristics